The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia

Sanz, Francisco; Gimeno-Cardona, Concepción; Tormo, Nuria; Fernández-Fabrellas, Estrella; Briones, M. Luisa; Cervera-Juan, Ángela; Blanquer-Olivas, Jose

doi:10.1016/j.vaccine.2016.01.038

Cited by 7 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three articles were included independently from the search engines (Figure 1). The papers were divided into two groups: those evaluating ARF in CAP but not its ventilatory management ( n = 12) [10,20,21,22,23,24,25,26,27,28,29,30] and those evaluating ventilatory management of ARF in CAP ( n = 17) [11,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46] (Tables S1 and S2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Management of Acute Respiratory Failure Due to Community-Acquired Pneumonia: A Systematic Review

et al. 2019

View full text Add to dashboard Cite

Community-acquired pneumonia (CAP) is a leading cause of mortality worldwide. CAP mortality is driven by the development of sepsis and acute respiratory failure (ARF). We performed a systematic review of the available English literature published in the period 1 January 1997 to 31 August 2017 and focused on ARF in CAP. The database searches identified 189 articles—of these, only 29 were retained for data extraction. Of these 29 articles, 12 addressed ARF in CAP without discussing its ventilatory management, while 17 evaluated the ventilatory management of ARF in CAP. In the studies assessing the ventilatory management, the specific treatments addressed were: high-flow nasal cannula (HFNC) (n = 1), continuous positive airway pressure (n = 2), non-invasive ventilation (n = 9), and invasive mechanical ventilation (n = 5). When analyzed, non-invasive ventilation (NIV) success rates ranged from 20% to 76% and they strongly predicted survival, while NIV failure led to an increased risk of adverse outcome. In conclusion, ARF in CAP patients may require both ventilatory and non-ventilatory management. Further research is needed to better evaluate the use of NIV and HFNC in those patients. Alongside the prompt administration of antimicrobials, the potential use of steroids and the implementation of severity scores should also be considered.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Miyashita et al showed that patients with ARF and Mycoplasma pneumoniae infection were exposed to adequate antibiotic therapy only after a significant delay [23]. In a study published by Sanz-Herrero, pneumococcal pneumonia caused by PCV-13 serotypes was associated with worse hypoxemia and a higher rate of respiratory complications [24].…”

Section: Resultsmentioning

confidence: 99%

Management of Acute Respiratory Failure Due to Community-Acquired Pneumonia: A Systematic Review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The countries with the most data sources were Spain (23 studies plus an additional study combining Italian and Spanish data) [5,25,28,49,[59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78] and the United Kingdom (14 studies) [80][81][82][83][84][85][86][87][88] followed by Italy (7 plus the additional study combining Italian and Spanish data) [42][43][44][45][46][47][48][49], the Netherlands (6 studies) [21,27,[50][51][52][53], Germany [26,[37][38]…”

Section: Studies Includedmentioning

confidence: 99%

Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

Torres

Blasi

Chalmers

et al. 2018

Respiratory Medicine

107

View full text Add to dashboard Cite

show abstract

“…Conjugation of the polysaccharide to a protein renders the vaccine immunogenic in infants and toddlers. [ 68 69 ] In January 2009, the pneumococcal protein-conjugate vaccine PCV7 containing capsular polysaccharides from 7 serotypes was nationally introduced to the neonatal vaccination program by the Saudi Ministry of Health based on the global experience in reduction of resistant organisms and IPD. PCV7 was then replaced by PCV13 in 2011.…”

Section: Types Of Pneumococcal Vaccinesmentioning

confidence: 99%

“…[ 8 ] PCV13 is covalently linked to a nontoxic protein which renders the polysaccharide antigenic in infants and toddlers. [ 68 69 ] It was approved in 2011 for the use in adult ≥50 years. [ 70 ] PCV13 contains polysaccharide from 13 common capsular types (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).…”

Section: Types Of Pneumococcal Vaccinesmentioning

confidence: 99%

The Saudi Thoracic Society pneumococcal vaccination guidelines-2016

Alharbi¹,

Albarrak²,

Al-Moamary³

et al. 2016

Ann Thorac Med

View full text Add to dashboard Cite

Streptococcus pneumoniae (pneumococcus) is the leading cause of morbidity and mortality worldwide. Saudi Arabia is a host to millions of pilgrims who travel annually from all over the world for Umrah and the Hajj pilgrimages and are at risk of developing pneumococcal pneumonia or invasive pneumococcal disease (IPD). There is also the risk of transmission of S. pneumoniae including antibiotic resistant strains between pilgrims and their potential global spread upon their return. The country also has unique challenges posed by susceptible population to IPD due to people with hemoglobinopathies, younger age groups with chronic conditions, and growing problem of antibiotic resistance. Since the epidemiology of pneumococcal disease is constantly changing, with an increase in nonvaccine pneumococcal serotypes, vaccination policies on the effectiveness and usefulness of vaccines require regular revision. As part of the Saudi Thoracic Society (STS) commitment to promote the best practices in the field of respiratory diseases, we conducted a review of S. pneumoniae infections and the best evidence base available in the literature. The aim of the present study is to develop the STS pneumococcal vaccination guidelines for healthcare workers in Saudi Arabia. We recommend vaccination against pneumococcal infections for all children <5 years old, adults ≥50 years old, and people ≥6 years old with certain risk factors. These recommendations are based on the presence of a large number of comorbidities in Saudi Arabia population <50 years of age, many of whom have risk factors for contracting pneumococcal infections. A section for pneumococcal vaccination before the Umrah and Hajj pilgrimages is included as well.

show abstract

The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia

Cited by 7 publications

References 36 publications

Management of Acute Respiratory Failure Due to Community-Acquired Pneumonia: A Systematic Review

Management of Acute Respiratory Failure Due to Community-Acquired Pneumonia: A Systematic Review

Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

The Saudi Thoracic Society pneumococcal vaccination guidelines-2016

Contact Info

Product

Resources

About